stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Return on equity
IDEAYA Biosciences, Inc.'s return on equity over the twelve months to 30 September 2026 was −38.5%, down 27.5 percentage points from fiscal 2025 (−10.9%). Over the past ten years it has ranged from −163.2% (fiscal 2019) to 106.2% (fiscal 2018); the current reading is higher than 78% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −10.9% | 21.75 |
| FY2024 | −32.7% | (9.39) |
| FY2023 | −23.3% | (5.26) |
| FY2022 | −18.0% | 1.89 |
| FY2021 | −19.9% | 3.19 |
| FY2020 | −23.1% | 140.06 |
| FY2019 | −163.2% | (269.35) |
| FY2018 | 106.2% | 69.51 |
| FY2017 | 36.7% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| BEAM Beam Therapeutics Inc. compare | −11.3% |
| ELVN Enliven Therapeutics, Inc. compare | −15.3% |
| DNLI Denali Therapeutics Inc. compare | −33.9% |
| IDYA IDEAYA Biosciences, Inc. | −38.5% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −319.8% |
| CELC Celcuity, Inc. compare | −1,433.7% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement